This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pfizer's Double Disappointment a Good Buying Opportunity

Stocks in this article: PFE AZN MRK BMY ZTS

NEW YORK ( TheStreet) -- Investors in Pfizer (PFE) have taken their lumps of late. On Friday AstraZeneca (AZN) the British drug manufacturer rejected a sweetened acquisition offer from Pfizer that was valued at more than $106 billion on the grounds that the amount undervalued the company. That's not surprising since AstraZeneca has a market cap of more than $101 billion.

>>Read More: Pfizer Needs AstraZeneca More Than Ever as Generics Increase
The second disappointment for Pfizer and its shareholders emerged before the markets opened today. The company reported sales profits fell 15% in the first quarter of 2014 on revenue of $11.4 billion. After the markets opened Pfizer fell 2.5% to less than $30 a share.

The biopharmaceutical giant has a plethora of products and brand names on which to drive earnings. These include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products. Among its consumer healthcare products there are Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands.

>>Read More: Why Intermune Stock Is Up Today
These helped Pfizer report "Adjusted Diluted EPS" for the quarter to hit 57 cents and its "Reported Diluted EPS" of 36 cents. These EPS numbers were slightly better than analysts expected, but the 15% profit decline was worse than predicted.

This 1-year chart illustrates the key financial trends leading up to the disappointing May 5 earnings release.

PFE Chart PFE data by YCharts

The company's quarterly diluted year-over-year EPS had precipitously declined in the last quarter of 2013 while its revenue growth had been mainly flat. The 9% quarterly year-over-year decline in revenue in the first quarter of 2014 is a wake-up call offering more insight as to why its CEO Ian Read is bound and determined to acquire AstraZeneca.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs